Skip to search formSkip to main contentSkip to account menu

alofanib

National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

BenzoatesSulfonamides

Narrower (1)

RPT835

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
A phase Ib study of alofanib, an allosteric FGFR2 inhibitor, in patients with advanced or metastatic gastric cancer.
TPS466Background: Fibroblast growth factor receptor 2 (FGFR2) is amplified or overexpressed in 3% to 61% of patients with gastric… 
2019
2019
ДОКЛИНИЧЕСКОЕ ТОКСИКОЛОГИЧЕСКОЕ ИЗУЧЕНИЕ АЛОФАНИБА — АЛЛОСТЕРИЧЕСКОГО ИНГИБИТОРА РЕЦЕПТОРА ФАКТОРА РОСТА ФИБРОБЛАСТОВ 2 ТИПА
Background. Inhibition of fibroblast growth factor receptor type 2 (FGFR2) appears to be appropriate in patients with tumors… 
2017
2017
Corrigendum to 'Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models' [Eur J Cancer 61 (2016) 20-28].
2016
2016
Abstract 2095: Toxicity of selective allosteric FGFR2 inhibition in preclinical studies
Alofanib (RPT835, Ruspharmtech LLC) is a novel selective allosteric inhibitor binding to the extracellular domain of FGFR2… 
2016
2016
151O Preclinical characterization of alofanib, a novel allosteric FGFR2 inhibitor
2015
2015
Antiangiogenic Activity of Alofanib, an Allosteric Inhibitor of Fibroblast Growth Factor Receptor 2
Alofanib is a potential allosteric inhibitor of FGFR2 used in oncology. The inhibitor blocks the extracellular part of the… 
2015
2015
Abstract 796: Alofanib, a novel allosteric FGFR2 inhibitor, shows potent antitumor activity in ovarian cancer with FGFR2 expression
Alofanib (formerly known as RPT835) is a novel allosteric FGFR2 inhibitor with activity in FGFR2-expressing triple-negative… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)